Abstract
Background: Non small cell carcinomas of lung, notably adenocarcinoma is associated with genetic mutations in EGFR (chromosome 7) , ALK (chromosome 2), ROS1(chromosome 6) . The patients harbouring these mutations are greatly benefited from tyrosine kinase inhibitor targeted chemotherapy. The prevalence of these mutations in central kerala has not been studied and documented. Aim: This study aims to analyse the frequency of different mutations in lung adenocarcinomas presenting to a oncology centre in kerala. Study Design: Descriptive study. Materials And Methods: The study spanned over a period of two years from 2019-2021. A total of 169 consecutive lung adenocarcinomas were studied. PCR for EGFR was done in 89 cases and were tested for the common mutations. ALK1 IHC using ALK-D5F3 clone and ROS with ROS-D4D6 clones were done in 40 cases. Results: EGFR mutation was present in 15 cases (17.44%). The most common age range was 40-60yrs. Two most common patterns were solid and acinar. ALK and ROS 1 mutation was found in 3 cases (7.5%) and 2 cases ( 5%) respectively. 4 cases (16.66%) of EGFR mutant lung adenocarcinoma patients had metastasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
